Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

afuresertib

An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic… Expand
Is this relevant?
2019
2019
PURPOSE Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors. Here the pan-AKT kinase… Expand
Is this relevant?
2018
2018
Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
BACKGROUND Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2017
2017
Abstract Malignant pleural mesothelioma (MPM), an asbestos‐related occupational disease, is an aggressive and incurable tumor of… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
2551Background: Patients (pts) with ovarian cancer (OC) often develop resistance to standard medical treatment (Rx) with platinum… Expand
Is this relevant?
2015
2015
Background Dual targeting of overlapping pathways in hematologic malignancies is an attractive therapeutic strategy to prevent… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PurposeTo identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
Background Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models… Expand
Is this relevant?